Skip to main content
Premium Trial:

Request an Annual Quote

Investment Bank Ups Invitrogen s Share Price Target to $83

NEW YORK, Dec. 16 (GenomeWeb News) - Investment bank UBS yesterday upped Invitrogen's price target to $83 after the company announced its latest acquisition.

 

As reported by GenomeWeb News yesterday, Xcyte Therapies agreed to sell its T cell expansion technology to Invitrogen for $5 million in cash along with a percentage of any sublicensing revenue Invitrogen derives from out-licensing the technology.

 

In the past month, Invitrogen has also reorganized its business to create a closer link between product development and its customer basewon a patent case on appeal, and signed distribution and co-marketing deals.

 

The company's average target price is $78.86.

 

Invitrogen's stock price has not moved significantly in today's mid-afternoon trading, declining .3 percent, or $.22 to $68.72.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.